CARLSBAD, Calif., Aug. 1, 2022 /PRNewswire/ — Active Motif Incorporated, a company with the vision of bringing┬áepigenetics more deeply into┬áprecision medicine, announced┬áthat┬áit┬áhas┬ánon-exclusively licensed┬áits┬áfoundational patents in┬átransposition for use in┬áCUT&Tag┬áepigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX). The┬áinnovations underlying these patents allow┬ámechanistic, translational, and clinical researchers to interrogate open chromatin with the goal of gaining an increased understanding of biological processes.┬á Through the licensing arrangement, Diagenode gains access to Active Motif’s patents, which include US9938524, EP2783001, US10689643, US11306307,┬áEP┬á2999784, and other related patent┬áapplications.
Details about Active Motif’s proprietary Cut&Tag-ITÔäó┬átechnology can be found at www.activemotif.com/catalog/1318/cut-tag-it-kit
About Active Motif
Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Its customers include scientists from academic and government institutions; biotechnology and pharmaceutical companies. Active Motif operates globally through its corporate headquarters in Carlsbad, California and offices in Shanghai China, Tokyo Japan and Waterloo Belgium. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.
Media Contact: Fritz Eibel, Active Motif Incorporated, Feibel@activemotif.com
 
SOURCE Active Motif
